- Home
- FSM vs BEAM Comparison
FSM vs BEAM Comparison
Compare FSM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSM | BEAM |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FSM | BEAM |
|---|---|---|
| Price | $8.33 | $33.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $14.00 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 4.8M | 2.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $38.01 | N/A |
| Revenue Next Year | N/A | $33.77 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $6.17 | $15.60 |
| 52 Week High | $13.85 | $36.88 |
Technical Indicators
Market Signals| Indicator | FSM | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 55.05 |
| Support Level | $7.92 | $26.96 |
| Resistance Level | $10.13 | $36.66 |
| Average True Range (ATR) | 0.37 | 2.34 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 14.44 | 58.10 |
Price Performance
Historical ComparisonAbout FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'voire, Mexico, and Peru. The company's segment consists of Mansfield, Sango, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d' Ivoire location.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.